AR
Anil Rajani
Intas Pharmaceuticals, Johnson & Johnson Pvt Ltd, Jawaharlal Institute of Post Graduate Medical Education, Maharaja Sayajirao University of Baroda, Cadila Pharmaceuticals Ltd
0000-0002-2477-9499
About
A medical affairs professional with >10 years of experience in the pharmaceutical industry
Employment
-
Intas Pharmaceuticals Assistant General Manager Medical Affairs2021 - Present
-
Johnson & Johnson Pvt Ltd Medical Advisor2017 - 2021
-
Cadila Pharmaceuticals Ltd2015 - 2017
-
Cadila Healthcare (India) Senior Scientist2014 - 2015
-
Ranbaxy Laboratories Ltd. Medical Advisor2013 - 2014
Education
-
Jawaharlal Institute of Post Graduate Medical Education Junior Resident2010 - 2013
-
Maharaja Sayajirao University of Baroda MBBS2004 - 2010
Projects & Funding
Projects & funding information is unavailable.
Publications (13)
- Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma. Save
- Treatment with nanosomal paclitaxel lipid suspension versus conventional paclitaxel in metastatic breast cancer patients – a multicenter, randomized, comparative, phase II/III clinical study Save
- Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma. Save
- Disease profile of Guillain-Barré syndrome among Indian patients receiving intravenous immunoglobulin: a real-world observational study Save
- Effectiveness and Safety of Rituximab Biosimilar in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results from a Prospective, Multicentre, Real-World Registry Study Save
- Real-world utilization and acceptance of biosimilar bevacizumab in metastatic colorectal cancer in India Save
- Real-world use and acceptance of biosimilar rituximab in oncology practice in India Save
- 1038P Nanosomal docetaxel lipid suspension (NDLS) monotherapy is effective and well-tolerated in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy Save
- 246P Nanosomal paclitaxel lipid suspension demonstrates better tumor response and safety versus conventional paclitaxel in patients with metastatic breast cancer Save
- Nanosomal docetaxel lipid suspension (NDLS) based (neo) adjuvant chemotherapy improves pathological complete response (pCR) in patients with breast cancer. Save